Metformin Treatment Is Associated with a Decreased Risk of Nonproliferative Diabetic Retinopathy in Patients with Type 2 Diabetes Mellitus: A Population-Based Cohort Study
Open Access
- 20 April 2020
- journal article
- research article
- Published by Wiley in Journal of Diabetes Research
- Vol. 2020, 1-12
Abstract
Purpose. To assess the relationship between metformin use and the severity of diabetic retinopathy (DR) in patients with type 2 diabetes mellitus (T2DM) and to investigate the effect of metformin dosage on reducing the incidence of DR. Methods. The study population included patients with newly diagnosed T2DM, who were aged ≥20 years and prescribed with antidiabetic drug therapy lasting ≥90 days, as identified using the National Health Insurance Research Database between 2000 and 2012. We matched metformin users and nonusers by a propensity score. Cox proportional hazard regression analyses were used to compute and compare the risk of developing nonproliferative diabetic retinopathy (NPDR) in metformin users and nonusers. Results. Overall, 10,044 T2DM patients were enrolled. Metformin treatment was associated with a lower risk of NPDR (aHR 0.76, 95% CI 0.68–0.87) and sight-threatening diabetic retinopathy (STDR, aHR 0.29, 95% CI 0.19–0.45); however, the reduction in risk was borderline significant for STDR progression among NPDR patients (aHR 0.54, 95% CI 0.28–1.01). Combination therapy of metformin and DPP-4i exhibited a stronger but inverse relationship with NPDR development (aHR 0.32, 95% CI 0.25–0.41), especially at early (Conclusion. Metformin treatment in patients with T2DM was associated with a reduced risk of NPDR, and a potential trend was found for a reduced STDR risk in patients who had previously been diagnosed with NPDR. Combining metformin with DPP-4i seemingly had a significantly beneficial effect against NPDR risk, particularly when aDCSI scores were low, and when metformin was prescribed early after T2DM diagnosis. These results may recommend metformin for early treatment of T2DM.Keywords
Funding Information
- China Medical University Hospital (DMR-108-208, MOUW108-CMAP-M-114-000406, M08G1114, NHIRD-105-071)
- Ministry of Health and Welfare (DMR-108-208, MOUW108-CMAP-M-114-000406, M08G1114, NHIRD-105-071)
- Ministry of Health and Welfare (DMR-108-208, MOUW108-CMAP-M-114-000406, M08G1114, NHIRD-105-071)
- National Health Research Institutes (DMR-108-208, MOUW108-CMAP-M-114-000406, M08G1114, NHIRD-105-071)
This publication has 45 references indexed in Scilit:
- Effects of saxagliptin on early microvascular changes in patients with type 2 diabetesCardiovascular Diabetology, 2014
- Effect of metformin on the proliferation, migration, and MMP-2 and -9 expression of human umbilical vein endothelial cellsMolecular Medicine Reports, 2012
- Diabetic Patients’ Medication Underuse, Illness Outcomes, and Beliefs About Antihyperglycemic and Antihypertensive TreatmentsDiabetes Care, 2009
- Management of Diabetic RetinopathyJAMA, 2007
- Contributions of Inflammatory Processes to the Development of the Early Stages of Diabetic RetinopathyJournal of Diabetes Research, 2007
- Overview of Epidemiologic Studies of Diabetic RetinopathyOphthalmic Epidemiology, 2007
- Too Much Ado about Propensity Score Models? Comparing Methods of Propensity Score MatchingValue in Health, 2006
- UKPDS 50: Risk factors for incidence and progression of retinopathy in Type II diabetes over 6 years from diagnosisDiabetologia, 2001
- Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33)The Lancet, 1998
- PHOTOCOAGULATION FOR DIABETIC MACULAR EDEMA: EARLY TREATMENT DIABETIC RETINOPATHY STUDY REPORT NO. 4International Ophthalmology Clinics, 1987